Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial

医学 熊去氧胆酸 安慰剂 临床终点 外科 胆结石 袖状胃切除术 无症状的 人口 内科学 中期分析 减肥 随机对照试验 肥胖 胃分流术 替代医学 病理 环境卫生
作者
Sylke Haal,Maimoena S. S. Guman,Thomas C. C. Boerlage,Yaïr I. Z. Acherman,L. M. de Brauw,Sjoerd C. Bruin,S. M. M. de Castro,Jeanin E. van Hooft,Arnold van de Laar,Daan Moes,Manon Schouten,Ruben Schouten,Ellert J. van Soest,Ruben N. van Veen,Claire E. E. de Vries,Paul Fockens,Marcel G. W. Dijkgraaf,Victor E. A. Gerdes,Rogier P. Voermans
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
卷期号:6 (12): 993-1001 被引量:25
标识
DOI:10.1016/s2468-1253(21)00301-0
摘要

Background Rapid weight loss is a major risk factor for the formation of cholesterol gallstones. Consequently, patients with morbid obesity undergoing bariatric surgery frequently develop symptomatic gallstone disease. This trial assessed the efficacy of ursodeoxycholic acid versus placebo for the prevention of symptomatic gallstone disease after bariatric surgery. Methods This multicentre, double-blind, randomised, placebo-controlled superiority trial enrolled patients with an intact gallbladder scheduled for laparoscopic Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy in three hospitals in the Netherlands. Patients were randomly assigned (1:1) by a web-based randomisation module to receive 900 mg ursodeoxycholic acid daily for 6 months or matched placebo. Randomisation was stratified by the presence of asymptomatic gallstones at baseline and type of surgery. Patients, clinicians, and study staff were masked to treatment allocation. The primary endpoint was symptomatic gallstone disease within 24 months, assessed in the modified intention-to-treat population (all randomly assigned eligible patients with any post-randomisation measurement). Prespecified subgroup analyses were done based on the stratification groups. Safety was assessed in all patients who took at least one dose of the study drug. This trial is registered with the Netherlands Trial Register, NL5954. Findings Between Jan 11, 2017, and Oct 22, 2018, 985 patients were randomly assigned to receive either ursodeoxycholic acid (n=492) or placebo (n=493). 967 patients were included in the modified intention-to-treat population, of whom 959 had data available for primary endpoint assessment. 189 (20%) patients had asymptomatic gallstones at baseline and 78 (8%) received a sleeve gastrectomy. Symptomatic gallstone disease occurred in 31 (6·5%) of 475 patients in the ursodeoxycholic acid group and in 47 (9·7%) of 484 patients in the placebo group (relative risk 0·67, 95% CI 0·43–1·04, p=0·071). Logistic regression showed a significant interaction between ursodeoxycholic acid and the presence of asymptomatic gallstones at baseline (p=0·046), with an effect of ursodeoxycholic acid in patients without (0·47, 0·27–0·84, p=0·0081), and no effect in patients with asymptomatic gallstones at baseline (1·22, 0·61–2·47, p=0·57). The effect was stronger in patients without gallstones at baseline undergoing RYGB (0·37, 0·20–0·71, p=0·0016), whereas the subgroup of patients undergoing sleeve gastrectomy was too small to draw clear conclusions. Adverse events were rare. In the ursodeoxycholic acid group, diarrhoea occurred in four (0·9%) of 444 patients and skin rash in two (0·5%) patients. In the placebo group, diarrhoea occurred in two (0·4%) of 453 patients and skin rash in two (0·4%) patients. The total number of serious adverse events did not significantly differ between the trial groups (75 [17%] in 444 patients in the ursodeoxycholic acid group and 102 [23%] in 453 patients in the placebo group). The most common serious adverse events were abdominal pain and internal hernia. No serious adverse event was attributed to the study drug. Interpretation Ursodeoxycholic acid prophylaxis did not significantly reduce the occurrence of symptomatic gallstone disease in all patients after bariatric surgery. In patients without gallstones before RYGB surgery, ursodeoxycholic acid treatment reduced the occurrence of symptomatic gallstone disease compared with placebo. Further research is needed to assess the efficacy of ursodeoxycholic acid after sleeve gastrectomy. Funding The Netherlands Organization for Health Research and Development, Zambon Netherlands BV, Foundation for Clinical Research of the Slotervaart Hospital, the Spaarne Gasthuis Academy, and Amsterdam Gastroenterology Endocrinology Metabolism.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
失眠善若完成签到,获得积分10
刚刚
刚刚
123发布了新的文献求助10
刚刚
JamesPei的应助被浙工大小采购采纳,获得10
刚刚
1秒前
1秒前
Qiao发布了新的文献求助10
2秒前
zhikaiyici发布了新的文献求助30
2秒前
洛克发布了新的文献求助10
3秒前
知足的憨人*-*完成签到,获得积分10
4秒前
4秒前
4秒前
大个的应助被桑桑采纳,获得10
4秒前
吃吃吃啥啦完成签到 ,获得积分10
5秒前
5秒前
清辉夜凝完成签到 ,获得积分10
5秒前
Felix发布了新的文献求助10
5秒前
kiwi发布了新的文献求助10
5秒前
6秒前
MUMU发布了新的文献求助10
6秒前
xxx完成签到 ,获得积分10
6秒前
7秒前
Hello的应助被布莱克采纳,获得10
7秒前
GIN的应助被李梨采纳,获得10
7秒前
8秒前
文艺宛筠发布了新的文献求助10
8秒前
8秒前
8秒前
8秒前
科研通AI6.3的应助被u596985采纳,获得10
8秒前
研友_VZG7GZ的应助被玩家666采纳,获得10
9秒前
木子木完成签到,获得积分10
9秒前
cheung发布了新的文献求助10
9秒前
ss完成签到,获得积分10
9秒前
LUsensei完成签到,获得积分20
10秒前
lkh发布了新的文献求助10
10秒前
周一发布了新的文献求助10
10秒前
充电宝的应助被何桉采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193653
求助须知:如何正确求助?哪些是违规求助? 9579816
关于积分的说明 21867585
捐赠科研通 7793288
什么是DOI,文献DOI怎么找? 3437343
关于科研通互助平台的介绍 2560779
邀请新用户注册赠送积分活动 2484193